Answers are grounded in this paper and cite their sources.
Introduction. Atopic Dermatitis (AD) is a complex, chronic, profoundly pruritic inflammatory dermatosis characterized by compromised epidermal barrier and relapsing-remitting course. While systemic therapies and targeted immunomodulators have revolutionized the management of moderate-to-severe disease presentations, the foundational pillar of AD management across all spectrums of severity remains the proactive restoration and maintenance of the stratum corneum. This comprehensive review summarizes clinical evidence regarding the pathophysiology of the atopic skin barrier, detailing the genetic implications of FLG loss-of-function mutations, the specific biochemical depletion of intercellular lipids (particularly ceramides), and the resultant microbiome dysbiosis driven by Staphylococcus aureus colonization. Materials and Methods. A systematic, rigorous search of peer-reviewed literature was conducted to synthesize current, evidence-based practices regarding skin barrier optimization in Atopic Dermatitis. A comprehensive literature search was executed across major medical and scientific databases, primarily utilizing PubMed/MEDLINE, Google Scholar, the Cochrane Central Register of Controlled Trials and Embase. Data were extracted focusing on the biochemical properties of the skin barrier, the comparative efficacy of various emollient formulations, and the specific clinical outcomes related to proactive versus reactive treatment modalities. The extracted data were analyzed and structured to provide a cohesive guide that translates complex dermatological science into actionable clinical management strategies. Results: The literature demonstrates that skin barrier dysfunction in Atopic Dermatitis is driven by FLG loss-of-function mutations, a distinct depletion of intercellular lipids (predominantly ceramides), and secondary Staphylococcus aureus microbiome dysbiosis. To counteract these defects, the evidence supports a foundational, multi-pronged barrier management approach. Successful strategies include evidence-based therapeutic bathing protocols, the precise application of targeted emollient classes, and the utilization of the "soak and smear" technique to lock in moisture. Furthermore, integrating these interventions with adjunctive pharmacotherapy, strict trigger avoidance, and comprehensive patient-centered education significantly enhances overall treatment efficacy and barrier integrity. Conclusions: Proactive, continuous maintenance of the stratum corneum remains the indispensable foundation of AD management, regardless of disease severity. Rather than relying on reactive treatments for acute flare-ups, clinicians must shift toward a holistic paradigm of continuous barrier optimization. This proactive strategy is essential not only for managing structural and microbial skin defects but also for potentially arresting the atopic march and alleviating the profound psychosocial burden carried by AD patients.
No takes yet. Share an insight, caveat, or question.
Kret et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: